MedTrace Logo

The Treatment of Depression With Botulinum Type A Toxin

NCT01392963 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-26

Study results available
· View outcomes & findings →

Summary

A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections. Subjects participating will have their photos taken and complete a questionnaire regarding their depression. They will see a psychiatrist at every visit who will assess their depression.

Conditions

Interventions

DRUG

botulinum toxin type A neurotoxin complex

29-40 U injection

DRUG

Placebo

29-40 U 0.9% NaCl injection

Sponsors & Collaborators

  • Seton Healthcare Family

    lead OTHER

Principal Investigators

  • Michelle Magid, MD · Seton Healthcare Family

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-11-30
Completion
2013-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392963 on ClinicalTrials.gov